Congenital bleeding disorders: hemophilia and von Willebrand's disease.
Treatment of hemophilia and von Willebrand's disease has become easier in recent years because of the development of more effective factor replacement products. The median age and the life expectancy of patients with hemophilia have risen markedly, as has the median age at death.
D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission; D000941:Antigens / Q000627:therapeutic use; D001779:Blood Coagulation Factors; D002543:Cerebral Hemorrhage / Q000628:therapy; D003613:Danazol / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000628:therapy; D006467:Hemophilia A / Q000628:therapy*; D006470:Hemorrhage / Q000628:therapy; D006509:Hepatitis B / Q000635:transmission; D006526:Hepatitis C / Q000635:transmission; D006801:Humans; D011247:Pregnancy; D013514:Surgical Procedures, Operative; D013927:Thrombosis / Q000209:etiology; D014081:Tooth Extraction; D014842:von Willebrand Diseases / Q000628:therapy*
D000941:Antigens; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin; D003613:Danazol